Targets › CHRNA4
28 programs from 26 companies in 202 trials: 62 Phase 2, 62 Phase 1, 55 Phase 4, 23 Phase 3; Psychiatry, Other, Oncology; next expected readout Nov 2026.
Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel…. (UniProt, P43681)
Open in Phaseline: the race on CHRNA4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| M.D. Anderson Cancer Center | [18F]-4FN PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2, CHRNB2, CHRNA4, Tubulin, OPRM1, CD274 | Phase 4 | Lymphoma; Tobacco Use Cessation; Cigarette Smoking-Related Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm … | Dec 2026 |
| University of California, Berkeley | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 4 | Dry Eye | Dec 2026 |
| Medical University of South Carolina | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 4 | Nicotine Dependence; Tobacco Use Disorder | Mar 2027 |
| Ottawa Heart Institute Research Corporation | Cytisinicline Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 4 | Tobacco | Apr 2027 |
| Ottawa Heart Institute Research Corporation | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 4 | Tobacco | Apr 2027 |
| University of Miami | Nicotine Polacrilex Neuronal acetylcholine receptor; alpha4/beta2 agonist | CHRNB2, CHRNA4 | Phase 4 | Smoking Cessation | Jul 2027 |
| Centre for Addiction and Mental Health | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 4 | Nicotine Dependence | Jan 2028 |
| M.D. Anderson Cancer Center | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 4 | Tobacco Use Cessation; Cigarette Smoking-Related Carcinoma | Feb 2028 |
| University of Wisconsin, Madison | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 4 | Smoking Cessation | Jul 2028 |
| Massachusetts General Hospital | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 4 | Nicotine Dependence | Sep 2028 |
| VA Office of Research and Development | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 4 | Veterans | Jun 2030 |
| Corporal Michael J. Crescenz VA Medical Center | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 4 | Schizophrenia | – |
| Abramson Cancer Center at Penn Medicine | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 3 | HIV/AIDS | Nov 2026 |
| University of Kansas Medical Center | Varenicline Tartrate Neuronal acetylcholine receptor; alpha4/beta2 agonist | CHRNB2, CHRNA4 | Phase 3 | Smoking Reduction | Dec 2026 |
| Population Health Research Institute | Cytisinicline Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 3 | Smoking (Tobacco) Addiction | Jan 2027 |
| Sir Mortimer B. Davis - Jewish General Hospital | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 3 | Acute Coronary Syndrome | Mar 2027 |
| Assistance Publique - Hôpitaux de Paris | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 3 | Smoking Cessation | Feb 2029 |
| University of Colorado, Denver | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 3 | Human Immunodeficiency Virus | – |
| University of California, Los Angeles | Cytisinicline α4β2 nicotinic acetylcholine receptor partial agonist | CHRNA4, CHRNB2 | Phase 2 | Smoking Cessation | Dec 2026 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Cytisinicline Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 2 | Inflammation | Dec 2026 |
| Washington State University | varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 2 | Alcohol Use Disorder (AUD) | Dec 2026 |
| McNeil | Nicotine Neuronal acetylcholine receptor; alpha4/beta2 agonist | CHRNB2, CHRNA4 | Phase 2 | Smoking Cessation | Oct 2027 |
| Vikas Kotagal | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 2 | Parkinson Disease | Jan 2029 |
| University of Oklahoma | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 2 | Smoking Cessation | Jun 2029 |
| Yale University | Varenicline Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | CHRNB2, CHRNA4 | Phase 2 | Tobacco Use; E-cigarette Use | Jun 2029 |
| JT International | Nicotine Neuronal acetylcholine receptor; alpha4/beta2 agonist | CHRNB2, CHRNA4 | Phase 1 | Smoking Behaviors; Nicotine Dependence; Tobacco Use Disorder; Tobacco … | – |
Smoking Cessation (11) Nicotine Dependence (7) Acute Myeloid Leukemia (6) Smoking (5) Tobacco-Related Carcinoma (4) Tobacco (3) Smoking (Tobacco) Addiction (3) Tobacco Use Disorder (3) Solid Tumor (3) Alcohol Use Disorder (AUD) (2) HIV/AIDS (2) Tobacco Use Cessation (2)
small molecule (25), mixed (1), protein or peptide (1)
Ottawa Heart Institute Research Corporation (2) M.D. Anderson Cancer Center (2) Washington State University (1) Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) University of Wisconsin, Madison (1) University of California, Berkeley (1) Abramson Cancer Center at Penn Medicine (1) Vikas Kotagal (1) University of Kansas Medical Center (1) Assistance Publique - Hôpitaux de Paris (1) Corporal Michael J. Crescenz VA Medical Center (1) Population Health Research Institute (1) University of California, Los Angeles (1) University of California, San Francisco (1) University of Oklahoma (1) Centre for Addiction and Mental Health (1) University of Colorado, Denver (1) JT International (1) Medical University of South Carolina (1) University of Pennsylvania (1)
CHRNB2 (28) OPRM1 (3) HTR2A (2) ADRB2 (1) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.